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Abstract: It is known that males and females respond differently to medicines and that differences 
in drug behaviour are due to inter-individual variability and sex specificity. In this work, we have 
examined the influence of pharmaceutical excipients on drug bioavailability in males and females. 
Using a rat model, we report that a portfolio of polyoxyethylated solubilising excipients 
(polyethylene glycol 2000, Cremophor RH 40, Poloxamer 188 and Tween 80) increase ranitidine 
bioavailability in males but not in females. The in vivo sex and excipient effects were reflected in 
vitro in intestinal permeability experiments using an Ussing chamber system. The mechanism of 
such an effect on drug bioavailability is suggested to be due to the interaction between the excipients 
and the efflux membrane transporter P-glycoprotein (P-gp), whose expression in terms of gene and 
protein levels were inhibited by the solubilising agents in male but not in female rats. In contrast, 
the non-polyoxyethylated excipient, Span 20, significantly increased ranitidine bioavailability in 
both males and females in a non-sex-dependent manner. These findings have significant 
implications for the use of polyoxyethylated solubilising excipients in drug formulation in light of 
their sex-specific modulation on the bioavailability of drugs that are P-gp substrates. As such, 
pharmaceutical research is required to retract from a ‘one size fits all’ approach and to, instead, 
evaluate the potential impact of the interplay between excipients and sex on drug effect to ensure 
effective pharmacotherapy. 
Keywords: pharmaceutical excipients; solubilizing agents; sex differences; P-glycoprotein; 
ranitidine; bioavailability; biopharmaceutical classification system (BCS); drug absorption; 
Polyethoxylated; multidrug resistance protein 1 (MDR1) 
 
1. Introduction 
Although it is widely appreciated that variability in drug performance is governed by a 
multitude of factors including genetics, age, race, and disease states, the impact of sex has 
traditionally been under-evaluated. As a result, women have been found to be 1.5 to 1.7 times more 
likely to develop a drug side effect when compared with their male counterparts [1,2]. Distinct sex-
related differences have been demonstrated in the efficacy of cardiovascular pharmacology [3], pain 
management [4] and cancer immunotherapy [5]. Moreover, the U.S. General Accounting Office 
(GAO) reported that eight out of the ten drugs withdrawn from the market over a twelve-year period 
since 1997 were due to greater risks of adverse effects in women [6]. Despite this, pre-clinical research 
has continued to display a tendency to focus on males in both cell and animal studies [7]. 
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Pharmaceutical excipients are intentionally co-formulated in drug delivery systems to aid the 
manufacturing processes and drug product performance related to patient acceptability, 
bioavailability and drug integrity during storage. In particular, excipients are listed as inactive 
ingredients by the Food and Drug Administration (FDA) who state that their contribution to 
increasing bioavailability would only be related to their physicochemical (and not physiological) role 
[8]. However, a growing body of evidence has challenged the inert nature of these agents [9]. For 
instance, in vivo studies demonstrated that sodium acid pyrophosphate [10] and mannitol [11] 
decreased small intestinal transit time which consequently decreased drug bioavailability by nearly 
40%. Similarly, high doses of the solubilising agent polyethylene glycol (PEG) 400 when co-
formulated with ranitidine accelerated small intestinal transit and consequently reduced oral 
bioavailability [12–14]. In follow-up studies with low doses of PEG 400, ranitidine bioavailability was 
increased in both humans [15] and rats [16,17]. This enhancement, however, was limited to males 
whilst no influence was observed in females [15–17]. 
Sex-specific differences in gastrointestinal physiology, such as the differential expression of 
membrane transporters, have been suggested to affect drug absorption and drug metabolism [18–20]. 
We have previously shown that the efflux transporter P-glycoprotein (P-gp) was responsible for 
mediating the variability in drug bioavailability between the sexes via its sex-specific interactions 
with the excipient PEG 400 [15–17,21]. In light of such a significant sex-specific modulation of drug 
bioavailability by PEG 400 and the scarcity of studies on the influence of sex on excipient behaviour, 
it is important to establish if other solubilising agents commonly used in drug formulations also 
exhibit different influences in bioavailability in males and females. As oral administration remains 
the most patient-acceptable route of drug delivery, and as many drugs currently available in the 
market are poorly water-soluble, solubilising agents are often included as excipients in drug 
formulations to improve oral bioavailability [22]. 
The aim of the work was, therefore, to investigate potential sex-specific influences of other 
solubilising excipients and specifically, polyoxyethylated excipients; polyethylene glycol 2000 (PEG 
2000), Cremophor RH 40, Poloxamer 188, Tween 80; and a non-polyoxyethylated excipient, Span 20 
(Figure 1). Precisely, their influence on; i) the in vivo bioavailability and in vitro intestinal permeation 
of the drug ranitidine, a P-gp substrate, and ii) the protein and gene expression of the efflux 
transporter P-gp in male and female rat models was determined. 
 
Figure 1. Chemical structures of tested excipients. 
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2. Materials and Methods 
2.1. Reagents and Materials 
Ranitidine hydrochloride, glacial acetic acid, and sodium acetate trihydrate were obtained from 
Sigma Aldrich (Dorset, UK). Polyethylene glycol 2000 (PEG 2000, Mw: 2000 g/mol), Span 20 (Mw: 346 
g/mol) and Tween 80 (Mw: 1310 g/mol) were purchased from Fluka (Dietikon, Switzerland). 
Poloxamer 188 (Mw: 4600 g/mol) and Cremophor RH 40 (Mw: 4600 g/mol) was from Agenda 
(Bradford, UK) and BASF (Cheadle, Germany), respectively. Water and acetonitrile were purchased 
from Fisher Scientific (Loughborough, UK) and were of HPLC grade. All other chemicals and kits are 
noted individually in the following methods 
2.2. Animals 
Male and female Wistar rats (8 weeks old, 250 ± 20 g) were used from Harlan UK Ltd. 
(Oxfordshire, UK). 
All animal work was conducted in accordance with the project licence (8002536), approved by 
the Home Office under the Animals (Scientific Procedures) Act 1986 on 7 June 2012. The rats were 
housed at room temperature (25 °C) and in a light-dark cycle of 12 h. They were caged in groups of 
six, allowed to move freely and provided with food and water before the experiment. The day before 
the experiment, the rats were fasted overnight and individually housed in metabolic cages. 
2.3. Investigation of the Influence of Excipients on the in Vitro Permeability of Ranitidine 
2.3.1. Tissue Preparation 
On the day of the experiment, rats were sacrificed with a CO2 euthanasia chamber (Schedule 1 
method) and the intestine was rapidly removed. In this study, the jejunum was the only intestinal 
segment assessed as it is the main site of absorption for orally administered drugs. In addition, 
previous studies confirmed that the jejunum is the optimal intestinal segment to reflect the in vivo 
influence of excipients specifically on ranitidine absorption [15,16]. The jejunum (10 cm from the 
ligament of Treitz) was cut, washed with cold KBR solution and put into beakers with Krebs-
Bicarbonate Ringer’s (KBR) solution on ice. This consisted of 10 mM D-glucose, 1.2 mM calcium 
chloride (CaCl2), 1.2 mM magnesium chloride (MgCl2), 115 mM sodium chloride (NaCl), 25 mM 
sodium bicarbonate (NaHCO3), 0.4 mM monopotassium phosphate (KH2PO4), 2.4 mM dipotassium 
phosphate (K2HPO4), pH 7.4 adjusted with sodium hydroxide/hydrochloric acid [23]. The tissue was 
allowed to rest for approximately 20 min to achieve a low tissue temperature and thus, minimise 
potential tissue damage during preparation. About 2–3 cm long pieces from the proximal part of the 
jejunum were opened along their mesenteric border. The jejunum segments were gently washed with 
KBR buffer to remove their contents. To obtain the mucosal tissue, sections were placed on an ice-
cold glass plate and the serosa was gently squeezed out with tweezers. 
2.3.2. Ussing Chamber Set-up 
Once the mucosal tissues were prepared, they were mounted on the vertical Ussing Chamber 
(Harvard Apparatus Inc., Holliston, MA, USA) as flat sheets on a 0.32 cm2 segment holder with 
needles for stabilisation. 5 mL KBR solution was added to each compartment of the Ussing Chamber 
and the solutions were gassed with an O2/CO2 (95%/5%) gas mixture. The chambers were tightly 
screwed and the entire assembly was controlled at 37 °C. 
To evaluate tissue integrity during experiments, tissue transepithelial electrical resistance 
(TEER) was measured using an EVOMX meter (World Precision Instruments Inc., WPI, 
Hertfordshire, UK). Any jejunum tissue that showed a TEER value lower than 40 Ω·cm2 at the 
beginning of the experiment was regarded as poorly viable and was excluded. Whenever TEER 
values decreased by more than 15% from the original value (measured at the end of the 20–30 min 
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equilibration period), the tissue was considered not to be viable and eliminated from the investigation 
[24]. 
2.3.3. Transport Study 
After an equilibrium period, the experiment was initiated by replacing the blank KBR solution 
in the donor compartment with pre-warmed ranitidine solution with and without pharmaceutical 
excipients. 100 μL of the receiver solution was taken to determine the drug concentration by HPLC 
every 30 min and replaced with an equal volume of a heated blank KBR solution. The receiver 
solution samples were kept at 4 °C until analysed for drug concentration by HPLC as described in 
Section 2.5. 
Previous experiments in our laboratory using PEG 400 showed that 0.5% w/v concentrations 
(12.5 μmol/mL) resulted in the highest enhancement of ranitidine intestinal permeability in the rat 
jejunum [25]. The same molarity concentrations were therefore used for the other excipients (PEG 
2000, Cremophor RH 40, Poloxamer 188, Tween 80 and Span 20) examined in this study. 
2.3.4. Calculation 
The apparent permeability coefficient (Papp) in each experiment, in cm/s, was calculated using 
the following equation: 
Papp = 𝑄𝐶 ×  𝐴 ×  𝑡 
where: Q (μmol) is the total amount of drug that permeated to the receiver compartment throughout 
the incubation time; C (μmol/mL) is the initial drug concentration in the donor side; A (cm2) is the 
diffusion area of the Ussing Chamber and; t (s) is the duration of experiment. 
2.4. Pharmacokinetic Experiments 
Each rat was weighed on the day of the experiment and orally administered ranitidine solution 
with or without a pharmaceutical excipient (PEG 2000 or Cremophor RH 40 or Poloxamer 188 or 
Tween 80 or Span 20) using an oral gavage needle. The dose of each excipient was 64 μmol/kg and is 
the same dose that caused the greatest increase in ranitidine bioavailability in a previous Wistar rats’ 
experiment with PEG 400 [16]. Comparable excipient concentrations were used in the in vitro and in 
vivo studies, taking the animal weight and administration volume into account. 
Following oral administration, approximately 250–300 μL of blood was collected from the rats’ 
tail vein into anticoagulant centrifuge tubes (BD Microtainer® K2E Becton, Dickinson and Company, 
Franklin Lakes, NJ, USA) at 0.5, 1.25, 2, 3, 4, 6, and 8 h. The rats were killed in a CO2 euthanasia 
chamber and about 1 mL of blood was taken by cardiac puncture. All blood samples were centrifuged 
at 10,000 rpm for 10 min on a Centrifuge 5804R (Eppendorf AG, Hamburg, Germany) within 8 h of 
collection. 50 μL of the supernatant was collected and placed into a 1.5 mL Eppendorf tube. The same 
volume of acetonitrile was added to precipitate the plasma proteins. The solution was vortex-mixed 
for 1 min to which 100 μL HPLC grade water was subsequently added. After vortex-mixing for 
another minute, the samples were centrifuged at 4 °C for 10 min at 10,000 rpm. The supernatant was 
collected and kept at −20 °C until analysis [16]. 
2.5. Methods of Analysis 
The samples were stored at −20 °C until analysis and allowed to thaw at room temperature 
before processing. The sample was subjected to HPLC-UV assay using a previously validated method 
[26]. The column used was a 5 μm Luna SCX (Phenomenex, UK); the mobile phase was a mixture of 
20:80 (acetonitrile):(0.1M sodium acetate pH = 5.0) with a flow rate of 2 mL/min and 40 μL of injection 
volume. 
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2.6. Pharmacokinetic Analysis 
Pharmacokinetic parameters, involving Cmax, tmax, AUC0–480 and AUC0–infinity was calculated by 
non-compartmental analyses using a free Microsoft Excel add-in, PKSolver [27]. 
2.7. Western Blot Analysis to Determine the Influence of Excipients on P-gp Protein Expression 
2.7.1. Animal Treatment 
On the day of the experiment, each rat was weighed and orally administered with a solution of 
one of the pharmaceutical excipients. Doses were the same as those used in Section 2.4. After 90 min, 
the rats were sacrificed in a CO2 euthanasia chamber. Then the intestines were rapidly removed and 
the jejunal segments were prepared as described in Session 2.3.1. 
90 min post dosing was selected following a previous on the influence of time using PEG 400 as 
the model excipient. P-gp expression quantification had been after 15 min, 30 min, 60 min, 90 min, 
120 min or 180 min post-dosing. The results showed a peak effect at 90 min post PEG dosing [17]. 
2.7.2. Sample Preparation 
The mucosal tissues (about 60 mg) were cut into small pieces and homogenised in 3 mL lysis 
buffer (freshly prepared with 50 mM Tris, 250 mM NaCl, 5 mM ethylenediaminetetraacetic acid 
(EDTA), 1 mM sodium orthovanadate (Na3VO4), 1 mM phenylmethysulfonyl fluoride (PMSF), 1% 
octylphenoxy poly(ethyleneoxy) ethanol (Nonidet P40) and protease inhibitor cocktail in phosphate 
buffered saline (PBS)) at 10,000 rpm for 20 s on ice with a T18 digital ULTRA-TURRAX® (IKA, 
Wilmington, CA, USA). The tissue homogenates were incubated at 4 °C for 2 h and then centrifuged 
at 10,000 rpm for 10 min. The total tissue protein was collected in the supernatants and its 
concentration was subsequently determined with the Pierce™ BCA Assay Protein kit (ThermoFisher, 
Loughborough, UK) according to the manufacturer’s instructions. 
2.7.3. Protein Analysis 
To measure the targeted P-gp level, samples containing 25 μg total protein were suspended in 
lithium dodecyl sulfate (LDS) sample loading buffer (Invitrogen, Carlsbad, CA, USA) and denatured 
for 10 min at 70 °C. As a molecular weight marker, 5 μL of Sharp Pre-Stained protein standard 
(Invitrogen) was loaded on each gel. 
Proteins in the samples were separated by electrophoresis in a NuPAGE™ Novex™ 4–12% Bis-
Tris gel (Invitrogen) and transferred to a nitrocellulose membrane with XCell SureLock™ Mini-Cell 
Electrophoresis System (Invitrogen) according to the manufacturer’s instructions. Nitrocellulose 
membranes were blocked with 3% bovine serum albumin (BSA) in TBS-T (0.1% Tween 20 in tris-
buffered saline) and incubated for 1 h at room temperature. For the detection of P-gp and reference 
protein (anti-beta-actin), blots were incubated for 1 h at room temperature with the respective 
primary antibodies diluted in 3% BSA in TBS-T: mouse monoclonal anti-P-gp (C-219 3:200; Enzo Life 
Science, Exeter, UK) and anti-β-actin mouse monoclonal antibody (1:2000; Sigma-Aldrich, Poole, UK). 
Bound antibodies were detected with affinity-purified rabbit anti-mouse IgG coupled to horseradish 
peroxidase (secondary antibody; Sigma-Aldrich, Dorset, UK) diluted 1:5000 in 3% BSA in TBS-T. 
After 1 h incubation with the secondary antibody conjugated with horseradish peroxidase, 
protein bands were visualised by chemiluminescence detection with Pierce™ ECL Western Blotting 
Substrate (ThermoFisher, Loughborough, UK), and subsequently photographed with a ChemiDoc 
XRS camera (Bio-Rad, Hertfordshire, UK). P-gp and reference protein bands were qualified using the 
Image Lab™ software (Bio-Rad, Hertfordshire, UK). To calculate the relative P-gp contents in the 
different samples, the reference protein band in each sample was set to 1 and the intensity of the P-
gp band was measured relative to it. 
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2.8. Real-Time Reverse-Transcription Polymerase Chain Reaction to Determine the Influence of Excipients 
on the Expression of P-gp Gene 
2.8.1. RNA Isolation 
Following the collection of mucosal tissues (as described in Section 2.7.1), the tissues were kept 
in RNA later® Stabilization Solution (Thermofisher, Loughborough, UK). Total RNA in each intestinal 
sample was isolated and purified with PureLink® RNA Mini Kit (Thermofisher, Loughborough, UK). 
RNA concentration was measured with Nanodrop 2000 (Thermofisher, Loughborough, UK) 
according to the manufacturer’s instructions. 
2.8.2. RNA Level Analysis 
Subsequently, the quantification of the target RNA was conducted as follows; 1 mg total RNA 
of each sample was reverse transcribed using the iScript™ cDNA Synthesis Kit (Bio-Rad, 
Hertfordshire, UK). To quantify the amount of P-gp mRNA (mdr1a and mdr1b), real-time PCR was 
performed on the 7500 Real Time PCR System (Applied Biosystems, Thermofisher, Loughborough, 
UK) using the method described in the study by MacLean et al. [28] 50 μL of the PCR reaction 
contained 25 μL of PowerUp™ SYBR Green PCR Master Mix (Thermofisher, Loughborough, UK), 
500 nM each of forward and reverse primers, and 1 μg of cDNA. Anti-beta actin was used for the 
normalisation and amplification of 1 μg cDNA respectively. Real-time PCR was carried out in 96 well 
PCR plates (Thermofisher, Loughborough, UK). The amplification program for all genes consisted of 
one pre-incubation cycle at 95 °C with a 10 min hold, followed by 45 amplification cycles with 
denaturation at 95 °C with a 10 s hold, an annealing temperature of 50 °C with a 10 s hold and an 
extension at 72 °C with a 10 s hold. Amplification was followed by a melting curve analysis which 
ran for one cycle with denaturation at 95 °C with a 1 s hold, annealing at 65 °C with a 15 s hold, and 
melting at 95 °C with a 1 s hold. Distilled water was included as a negative control in each run to 
access specificity of primers and possible contaminants. 
Primers (shown in Table 1) were designed by primer-BLAST searching with publicly available 
sequence information of the GeneBank of the National Center for Biotechnology Information (NCBI) 
and purchased from Eurofins (Eurofins Genomics, Germany). 
Table 1. Primers used for the analysis of P-gp gene expression by real-time qPCR. 













2.8.3. Data Analysis 
Relative expression of mdr1a and mdr1b mRNA in different intestinal segments were calculated 
using the 7500 software (version 2.0.6, Thermofisher, Loughborough, UK). The average of the 
threshold cycle (Ct) values for tested genes (mdr1a and mdr1b) and the internal control (anti-beta actin) 
was taken. The differences between Ct values for tested genes and internal control (∆Ct) were then 
calculated for all the experimental samples. 
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2.9. Statistical Analysis 
All results are expressed as mean ± SD (n = 6). The control and test group data were analysed by 
one-way ANOVA, followed by post-hoc Tukey analysis with a 95% confidence interval using IBM 
SPSS Statistics 16 (SPSS Inc., Chicago, Illinois, USA). A minimum p-value of 0.05 was used as the 
significance level for the tests. 
3. Results 
3.1. In Vitro Intestinal Permeability 
In the male rat jejunum, the in vitro intestinal permeability of ranitidine increased in the presence 
of PEG 2000, Cremophor RH 40, Poloaxamer 188 and Tween 80 by 36%, 33%, 47% and 35% 
respectively (Figure 2). In contrast, no enhancement was observed in female rats in the presence of 
these excipients when compared with the control. A distinctly different result was observed for Span 
20 where ranitidine permeability significantly increased in both male and female rats by 22% and 
23% respectively (p < 0.05). 
 
Figure 2. Percentage change in in vitro ranitidine permeability in the rat jejunum in the presence of 
the different excipients in males and females (mean ± SD, n = 6). * Values are statistically different 
when compared to the control (i.e. no excipient) and the excipient groups at p < 0.05. 
3.2. In Vivo Bioavailability 
The ranitidine plasma concentration–time profiles in the presence and absence of these 
excipients for males and females are shown in Figure 3. The in vivo bioavailability of ranitidine (area 
under the curve, 0-infinity) was significantly increased in male rats in the presence of PEG 2000, 
Cremophor RH 40, Poloxamer 188 and Tween 80 by 62%, 35%, 44%, and 67% respectively whilst no 
significant changes were observed in female rats (Figure 4). The co-formulation of ranitidine and 
Span 20, however, significantly increased drug bioavailability in both males and females by 24% and 
31% respectively when compared with the controls (Figure 4 and Table 2). 






Figure 3. In vivo mean plasma concentration-time curve of ranitidine in the absence (control) or 
presence of excipients in male (a) and female (b) rats (n = 6). 
 
Figure 4. Percentage change in ranitidine bioavailability (AUC0–infinity) in the presence of excipients in 
male and female Wistar rats (mean ± SD, n = 6). * Values are statistically different between the control 
(i.e. no excipient) and the excipient groups at p < 0.05. 
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Table 2. Effect of excipients on the pharmacokinetic parameters of ranitidine in male and female 
Wistar rats (mean ± SD, n = 6). * Values are statistically different between the control and excipient 
groups at p < 0.05. 
Pharmacokinetic Parameters 
Control 
(i.e. no excipient) PEG 2000 Cremophor RH 40 Poloxamer 188 Tween 80 Span 20 
Male 
AUC0–480 (μg.min/mL) 391 ± 108 680 ± 167 * 563 ± 94 *  561 ± 112 * 670 ± 146 * 546 ± 80 * 
AUC0–infinity/∞ (μg.min/mL) 485 ± 109 784 ± 171 * 655 ± 85 * 700 ± 77 * 809 ± 212 * 603 ± 91 * 
cmax (μg/mL) 2.0 ± 0.8 3.5 ± 0.7 * 3.4 ± 0.6 * 3.9 ± 0.7 * 3.8 ± 0.9 * 3.8 ± 0.5 * 
tmax (min) 146 ± 110 150 ± 79  155 ± 61  195 ± 72  160 ± 128  157 ± 95  
Female 
AUC0–480 (μg.min/mL) 437 ± 59  454 ± 74  490 ± 27  422 ± 61  507 ± 33  613 ± 76 * 
AUC0–infinity/∞ (μg.min/mL) 517 ± 47  512 ± 66  544 ± 26  527 ± 61  596 ± 52  676 ± 79 * 
cmax (μg/mL) 2.5 ± 0.2  1.8 ± 0.7  2.1 ± 0.3  1.9 ± 0.5  2.6 ± 0.4  3.2 ± 0.6  
tmax (min) 127 ± 75  107 ± 42  98 ± 38  190 ± 45  150 ± 35  70 ± 65  
3.3. Relative P-glycoprotein Abundance 
With regards to P-gp protein abundance, all the solubilising excipients decreased the intestinal 
expression of P-gp by 31–43% in male rats. No significant observations were demonstrated in the 
intestinal expression of P-gp in female rats, except in the presence of Span 20 where protein levels 
decreased by 59% when compared with the control (Figure 5). 
 
Figure 5. Percentage change in P-gp protein level in the presence of excipients in male and female 
Wistar rats (mean ± SD, n = 6). * Values are statistically different between the control (i.e, no excipient) 
and the excipient groups at p < 0.05. 
3.4. P-glycoprotein Gene Expression 
In terms of P-gp gene expression, the solubilising excipients reduced mdr1a mRNA expression 
in the presence of PEG 2000, Cremophor RH 40, Poloxamer 188 and Tween 80 by 33 – 60% in male 
rats but had no influence in females. In the presence of Span 20, however, mdr1a expression in both 
male and female rats significantly reduced by 51% and 43% respectively (Figure 6). No obvious trend 
was observed in mdr1b mRNA expression in males and females in the presence of these excipients 
(Supplementary Figure S1). 
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Figure 6. Percentage changes in mdr1a mRNA expression in the presence of excipients in male and 
female Wistar rats (mean ± SD, n = 6). * Values are statistically different between the control (i.e. no 
excipient) and the excipient groups at p < 0.05. 
4. Discussion 
Our results add to the growing body of evidence that challenges the ‘inert’ nature of excipients. 
In addition, we show that the influence of certain excipients is subject to the sex of the species. The 
polyoxyethylated excipients, PEG 2000, Cremophor RH 40, Poloxamer 188 and Tween 80 all 
increased the in vivo bioavailability of ranitidine in male but not in female rats. The differential 
increase in in vivo bioavailability between the sexes (Figures 3 and 4) was reflected in the in vitro 
permeability of ranitidine due to the presence of these excipients (Figure 2). 
Moreover, the excipients significantly increased ranitidine in vitro jejunal permeability and in 
vivo bioavailability in males and this was reflected in their influence on the relative P-gp level 
expressed; all the excipients exhibited inhibitory influences on the activity and expression of P-gp. 
Interestingly, in females, the excipients did not change relative P-gp expression (Figures 5 and 6). 
In contrast, Span 20, a non-polyoxyethylated excipient, enhanced in vitro and in vivo 
bioavailability in both males and females showing no sex differences. Consequently, the 
enhancement of drug bioavailability in males may be related to the polyoxyethylated structures of 
PEG 2000, Cremophor RH 40, Poloxamer 188 and Tween 80. 
In agreement with our previous study on PEG 400 [18], PEG 2000 is a modulator of the efflux 
transporter P-gp, although this effect is limited to male rats. PEGs can inhibit the efflux transport of 
P-gp to increase the bioavailability of P-gp substrates. For example, PEG 2000 and PEG 20,000 reduce 
the secretory transport of P-gp-mediated Rhodamine 123 in male rats [29,30]. Our study, however, 
confirms that PEG 2000 is capable of modifying the activity and expression of P-gp to enhance the 
bioavailability of P-gp-mediated drugs in a sex-dependent manner. With regards to Cremophor RH 
40, its effect on the P-gp substrate digoxin was to significantly increase its bioavailability by 22% in 
males [31]. In the case of Tween 80, Rege et al. reported that the permeability of Rhodamine 123 (a P-
gp substrate) was increased from the apical-to-basolateral membrane but decreased from the 
basolateral-to-apical membrane in Caco-2 cell monolayers in the presence of the excipient [32]. At 
concentrations below 0.01% (w/v), Tween 80 was able to decrease the expression of P-gp which 
resulted to an enhanced uptake of P-gp-mediated Rhodamine 123 [33]. In addition, this study is the 
first to describe the in vivo effects of Tween 80 on the function of P-gp with in vitro results strongly 
proving its effects. However, herein, Tween 80 not only proved its active interaction with P-gp but 
also demonstrated its sex-dependent interaction on P-gp function. 
The underlying mechanism behind this sex-based phenomenon is unclear although a number of 
hypotheses are possible. Firstly, an innately higher intestinal P-gp expression was reported in male 
rodents and male human species when compared with females [34,35]. This, however, cannot be 
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considered as the sole reason for sex-differences as variances in absorption is only reflected in some 
P-gp substrates even in the absence of studied excipients. Secondly, surfactants have been shown to 
modulate P-gp activity via altering the fluid environment of the lipid cell membrane. This 
consequently led to a reduction of ATPase activity as well as a decrease in affinity of P-gp for ATP in 
conjunction with a depletion of intracellular ATP [29]. The differences of P-gp ATPase activity 
between males and females are unknown, however, all tested excipients, including Span 20, have 
been reported to alter the ATPase activity of P-gp. This can also influence its efflux protein transporter 
function on the intestinal membrane [36–39]. If P-gp ATPase activity differed between males and 
females, a sex-related difference should have been seen in the intestinal absorption of ranitidine in 
the presence of Span 20. Moreover, several other studies have further shown that non-ionic 
surfactants are effective at modifying P-gp ATPase activity at concentrations lower than their critical 
micelle concentration (CMC). This inhibitory effect, however, is decreased at or above the CMC value 
of the surfactant due to micelle formation [40,41]. As all excipient doses used in this study were higher 
than their CMC (Cremophor RH 40, 0.01% [42]; Poloxamer 188, 0.2% [43]; Tween 80, 0.0014% [44]; 
and Span 20, 0.07% [45], the sex-related modification on the P-gp ATPase activity is less likely to be 
a plausible reason behind this phenomenon. 
Interestingly, the alteration in membrane lipid environment can also lead to changes in P-gp 
protein expression. P-gp is highly sensitive to the lipid environment; the membrane lipid bilayer can 
consequently be affected in the presence of excipients such as PEG 2000, Cremophor RH 40, 
Poloxamer 188 and Tween 80 in this study which all contain hydrophilic ethylene oxide (EO) units. 
The interaction between excipients and P-gp in the lipid membrane is due to transient hydrogen bond 
formation of EO groups with hydrogen bond donor groups of the transmembrane domains of P-gp 
[46]. As such, the EO unit can be inserted into the polar head group regions of the cell membrane [47–
49] and elicit a change in the lipid environment. Lastly, female rat intestinal P-gp has been found to 
be less sensitive to pharmaceutical excipients than in males [18]. Based on the aforementioned 
findings, the authors have suggested that this may be due to the female intestinal membrane being 
more resilient to changes in fluidity and/or undergoing slower epithelial renewal rates than their 
male counterparts. 
The expression of P-gp was also recently reported to be linked to a group of nuclear receptors 
such as the nuclear receptor proteins retinoic acid receptor (RAR), farnesoid receptor (FXR), steroid-
activated receptor (SXR) and pregnane receptor (PXR, in rodents) which have lipid ligands [50–52]. 
The ability of nuclear receptors to cross-react with the protein binding sites and to govern similar 
membrane regulatory cascades indicates a bi-directional transcriptional regulatory pathway between 
lipids and P-gp [53–55]. However, the interaction between excipients and nuclear receptors and the 
qualification of the nuclear receptors are unknown. Therefore, the excipients studied in this paper 
may interact with the receptor pathways, resulting in the observed reduction in P-gp expression in a 
similar manner to previously reported lipid agents, Peceol® and Gelucire® 44/14 [56]. 
5. Conclusion 
In this study, we identified that a number of solubilising agents including PEG 2000, Cremophor 
RH 40, Poloxamer 188 and Tween 80 were capable of reducing the activity and expression of intestinal 
P-gp, resulting in the enhancement in ranitidine bioavailability in male rats, but not in females. In 
contrast, Span 20 enhanced bioavailability in both male and female rats in a non-sex-dependent 
manner. The underlying mechanism for the sex-related influence of excipients on transporters may 
be related to the chemical structure of the excipients since all the tested excipients, bar Span 20, are 
polyoxyethylated. The sex differences demonstrated by this study highlights the need for the 
screening of ‘inert’ pharmaceutical excipients in terms of their selection and use for oral drug 
development. In particular, the results reported here are of clinical importance for P-gp drug 
substrates. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Percentage 
changes in mdr1b mRNA expression in the presence of excipients in male and female Wistar rats (mean ± SD, n 
= 6). 
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